Sanofi India Limited (IN:SANOFI)
:SANOFI
SANOFI Stock Chart & Stats
₹4142.75
₹54.40(0.91%)
At close: 4:00 PM EST
₹4142.75
₹54.40(0.91%)
Day’s Range― - ―
52-Week Range₹3,151.05 - ₹6,717.50
Previous CloseN/A
Volume15.46K
Average Volume (3M)3.77K
Market Cap
₹75.19B
Enterprise Value₹72.55B
Total Cash (Recent Filing)₹3.13B
Total Debt (Recent Filing)₹209.00M
Price to Earnings (P/E)38.1
Beta0.84
Next Earnings
Apr 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.73%
Share Statistics
EPS (TTM)26.80
Shares Outstanding23,030,000
10 Day Avg. Volume3,778
30 Day Avg. Volume3,766
Financial Highlights & Ratios
PEG Ratio6.96
Price to Book (P/B)12.56
Price to Sales (P/S)5.12
P/FCF Ratio22.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)170.03
Revenue Forecast (FY)₹19.55B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage gives Sanofi India durable financial flexibility to fund operations, absorb shocks, and support strategic initiatives without heavy refinancing. This conservatism supports creditworthiness and long-term resilience, enabling capital allocation to growth or shareholder returns when opportunities arise.
Strong Cash GenerationConsistent FCF that closely tracks earnings and a large FCF increase in 2025 reflect high earnings quality and internal funding capacity. Durable cash generation supports sustainable dividends, reinvestment in brands or therapies, and optional M&A without over-reliance on external financing.
Diversified, Repeat-demand PortfolioA balanced mix of chronic therapy franchises and branded consumer health provides recurring revenue and lowers volatility versus single-product exposure. Chronic care drives repeat prescriptions while consumer brands add retail reach, supporting steadier demand and long-term revenue resilience.
Bears Say
Weakening Revenue TrendA multi-year choppy top-line and a 2025 revenue decline suggest slower market traction or competitive pressures. Persistent topline weakness can constrain reinvestment, limit economies of scale, and make earnings and cashflow more sensitive to cost or pricing shocks over the medium term.
Material Gross Margin CompressionA sharp, sustained fall in gross margins signals structural margin pressure from pricing, input-costs, or adverse mix shifts. Lower gross margins reduce operating leverage and durable earnings power, forcing reliance on cost cuts or price recovery to restore past profitability levels.
Decline In Equity BaseA falling equity base can artificially boost ROE while eroding the capital buffer available for growth or shocks. If driven by distributions or balance-sheet restructuring, it may reduce long-term financial flexibility and increase sensitivity to adverse operating or market events.
Sanofi India Limited News
SANOFI FAQ
What was Sanofi India Limited’s price range in the past 12 months?
Sanofi India Limited lowest stock price was ₹3151.05 and its highest was ₹6717.50 in the past 12 months.
What is Sanofi India Limited’s market cap?
Sanofi India Limited’s market cap is ₹75.19B.
When is Sanofi India Limited’s upcoming earnings report date?
Sanofi India Limited’s upcoming earnings report date is Apr 28, 2026 which is in 22 days.
How were Sanofi India Limited’s earnings last quarter?
Sanofi India Limited released its earnings results on Feb 25, 2026. The company reported ₹26.8 earnings per share for the quarter, missing the consensus estimate of ₹45.05 by -₹18.25.
Is Sanofi India Limited overvalued?
According to Wall Street analysts Sanofi India Limited’s price is currently Overvalued.
Does Sanofi India Limited pay dividends?
Sanofi India Limited pays a Semiannually dividend of ₹75 which represents an annual dividend yield of 4.73%. See more information on Sanofi India Limited dividends here
What is Sanofi India Limited’s EPS estimate?
Sanofi India Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sanofi India Limited have?
Sanofi India Limited has 23,030,000 shares outstanding.
What happened to Sanofi India Limited’s price movement after its last earnings report?
Sanofi India Limited reported an EPS of ₹26.8 in its last earnings report, missing expectations of ₹45.05. Following the earnings report the stock price went up 1.5%.
Which hedge fund is a major shareholder of Sanofi India Limited?
Currently, no hedge funds are holding shares in IN:SANOFI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sanofi India Limited
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singaporem and internationally. It provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, central nervous system, anti-infective, epilepsy, allergy and vitamins, anti-histamines, and minerals and supplements under the Lantus, Toujeo, Clexane, Amaryl, Cardace, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands through independent distributors. The company also exports its products. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.
Technical Analysis
Abbott India Limited
―
Cipla Ltd
―
Dr. Reddy's Laboratories Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―